I was disappointed that the Thursday news about 1.1 billion doses with the COVAX agreement didn't push back over $300. Next news events should include final efficacy data on the UK P3 study, UK EUA, and EU finalization of dosage deal plus - hopefully, their EUA also.
In the meantime, US P3 trial participants are receiving letters stating that trial enrollment is complete and they are planning for a cross-over (vaccinated get placebo and vice versa) sometime by April. Company needs to put out a PR on their fully enrolled trial.